These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38127586)

  • 81. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Spontaneous disappearance of the inhibitor during emicizumab therapy in a patient with mild hemophilia A].
    Matsumoto A; Ogawa Y; Uchiyama Y; Ishikawa T; Naito C; Kobayashi N; Miyazawa Y; Ishizaki T; Inoue M; Moteki Y; Kitazawa S; Murakami M; Matsumoto N; Handa H
    Rinsho Ketsueki; 2022; 63(10):1392-1396. PubMed ID: 36351645
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
    Oldenburg J; Shima M; Kruse-Jarres R; Santagostino E; Mahlangu J; Lehle M; Selak Bienz N; Chebon S; Asikanius E; Trask P; Mancuso ME; Jiménez-Yuste V; von Mackensen S; Levy GG
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28474. PubMed ID: 32776489
    [TBL] [Abstract][Full Text] [Related]  

  • 85. CHIEF: A retrospective self-control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis.
    Mashiach D; Mead P; Carneiro K; Malvar J; Knight S; Young G
    Pediatr Blood Cancer; 2024 Dec; 71(12):e31351. PubMed ID: 39367598
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study.
    Mancuso ME; Mahlangu J; Sidonio R; Trask P; Uguen M; Chang T; Shima M; Young G; Oldenburg J; von Mackensen S
    Haemophilia; 2020 Nov; 26(6):1009-1018. PubMed ID: 33084175
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.
    Sun SX; Frick A; Balasa V; Roberts JC
    Expert Rev Hematol; 2022 Oct; 15(10):943-950. PubMed ID: 36000620
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab.
    Valls R; Wagg J; Paz-Priel I; Man G; Artigas L; Jaccard G; Coma M; Schmitt C
    Sci Rep; 2023 Jun; 13(1):10078. PubMed ID: 37344529
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
    Castaman G; Santoro C; Coppola A; Mancuso ME; Santoro RC; Bernardini S; Pugliese FR; Lubrano R; Golato M; Tripodi A; Rocino A; Santagostino E; ; Biasoli C; Borchiellini A; Catalano A; Contino L; Coluccia A; Cultrera D; De Cristofaro R; Di Minno G; Fabbri A; Franchini M; Gamba G; Giuffrida AC; Gresele P; Giampaolo A; Hassan HJ; Luciani M; Marchesini E; Marino R; Mazzucconi MG; Molinari AC; Morfini M; Notarangelo LD; Peccarisi L; Peyvandi F; Pollio B; Rivolta GF; Ruggieri MP; Sargentini V; Schiavoni M; Sciacovelli L; Serino ML; Siragusa S; Tagliaferri A; Testa S; Tosetto A; Zampogna S; Zanon E
    Blood Transfus; 2020 Mar; 18(2):143-151. PubMed ID: 31657709
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
    Kruse-Jarres R; Peyvandi F; Oldenburg J; Chang T; Chebon S; Doral MY; Croteau SE; Lambert T; Kempton CL; Pipe SW; Ko RH; Trzaskoma B; Dhalluin C; Bienz NS; Niggli M; Lehle M; Paz-Priel I; Young G; Jiménez-Yuste V
    Blood Adv; 2022 Dec; 6(24):6140-6150. PubMed ID: 35939785
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Hemophilia A: Emicizumab monitoring and impact on coagulation testing.
    Nardi MA
    Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
    Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
    Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
    Callaghan MU; Asikanius E; Lehle M; Oldenburg J; Mahlangu J; Uguen M; Chebon S; Kruse-Jarres R; Jiménez-Yuste V; Shima M; Trask P; Kempton CL; Kessler CM; Levy GG; Peyvandi F
    Res Pract Thromb Haemost; 2022 Aug; 6(6):e12782. PubMed ID: 36171959
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms.
    Lillicrap D; Fijnvandraat K; Young G; Mancuso ME
    Expert Rev Hematol; 2020 Apr; 13(4):313-321. PubMed ID: 32186928
    [No Abstract]   [Full Text] [Related]  

  • 96. A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.
    Yoneyama K; Schmitt C; Kotani N; Levy GG; Kasai R; Iida S; Shima M; Kawanishi T
    Clin Pharmacokinet; 2018 Sep; 57(9):1123-1134. PubMed ID: 29214439
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab.
    Garcia J; Zia A
    Pediatr Blood Cancer; 2021 May; 68(5):e28942. PubMed ID: 33559300
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.
    Shima M; Nagao A; Taki M; Matsushita T; Oshida K; Amano K; Nagami S; Okada N; Maisawa S; Nogami K
    Haemophilia; 2021 Jan; 27(1):81-89. PubMed ID: 33236410
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Emicizumab for acquired haemophilia A: A case series.
    Engelen MM; Vandesande J; De Bent J; Van Laer C; Labarque V; Jacquemin M; Peerlinck K; Hermans C; Verhamme P; Vanassche T
    Haemophilia; 2023 Jul; 29(4):1049-1055. PubMed ID: 37276345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.